30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study
Crossref DOI link: https://doi.org/10.1186/s13756-017-0286-9
Published Online: 2017-12-06
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zilberberg, Marya D.
Nathanson, Brian H.
Sulham, Kate
Fan, Weihong
Shorr, Andrew F.
Funding for this research was provided by:
The Medicines Company (NA, NA)